By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Neurogenesis, Inc. (NEUN)

OTC Currency in USD
$0.00
$0.00
+900.00%
Last Update: 29 Aug 2025, 00:00
$82.26K
Market Cap
0.00
P/E Ratio (TTM)
Forward Dividend Yield
$0.00 - $0.00
52 Week Range

NEUN Stock Price Chart

Explore Neurogenesis, Inc. interactive price chart. Choose custom timeframes to analyze NEUN price movements and trends.

NEUN Company Profile

Discover essential business fundamentals and corporate details for Neurogenesis, Inc. (NEUN) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

8 Jun 1998

Employees

CEO

Tal Gilat

Description

Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.

NEUN Financial Timeline

Browse a chronological timeline of Neurogenesis, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

No results found.

NEUN Stock Performance

Access detailed NEUN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run